News

Touch is a fundamental, yet scarcely understood, sense. Now, the team led by Gary Lewin at the Max Delbrück Center has discovered a second ion channel associated with touch perception. Elkin1 could be a target for pain therapy, the team writes in “Science”.

Cell-based immunotherapies, particularly lab-produced immune cells known as CAR T cells, show promise in treating various cancers. But how do we produce effective ones? Gaetano Gargiulo from the Max Delbrück Center will develop a novel screening tool, supported by an ERC Proof of Concept Grant.

Diseases can emerge when the body’s production of serotonin is out of whack. Researchers led by Michael Bader from the Max Delbrück Center have discovered a therapeutic agent that brings down high levels of this hormone. Their start-up, Trypto Therapeutics, aims to develop the drug for the market.

A data gap that threatens timely diagnosis and treatment for half the population, the visibility of female researchers in Wikipedia, and myriads of microbes in and on our bodies – the Max Delbrück Center's program for the Berlin Science Week 2023 is focused on dimensions of diversity.

After spending many years researching together, a group of scientists has founded CARTemis Therapeutics, a spin-off from the Max Delbrück Center. Uta Höpken, Armin Rehm, Anthea Wirges, and Mario Bunse want to use novel CAR T-cell therapies to help patients with cancers that are currently untreatable.

Many people with post-COVID syndrome who suffer from fatigue six months after a coronavirus infection are still severely physically impaired up to 20 months afterward. The study by ECRC researcher Judith Bellmann-Strobl and her colleagues was published in “eClinicalMedicine.”

Cancer cells are capable of escaping chemotherapy and radiotherapy by activating a signaling pathway that prevents them from dying. Researchers led by Claus Scheidereit at the Max Delbrück Center have now described in Cell Chemical Biology two new compounds that block this escape route.

The stem cell therapy developed by MyoPax, a spin-off from the Max Delbrück Center and Charité, could soon be helping children with previously incurable muscle diseases thanks to an accelerated approval process. The necessary clinical trial will start in the fall.

Researchers at BIH and the Max Delbrück Center have developed a new approach for vaccines against coronaviruses using modified spike proteins with lower binding affinity. This method could make vaccinations more effective, the team writes in the "European Journal of Immunology".

A new tool can identify cells that are actively responding to a SARS-CoV-2 infection. As reported in "Science Advances" by the Gargiulo lab, it can be used to screen for effective COVID-19 therapies and can be tailored to study other viruses as well.